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Abstract  
 
A EULAR-ACR working group consisting of practicing and academic rheumatologists, a 
rheumatology researcher and a patient advocate created a succinct general statement 
describing rheumatic and musculoskeletal diseases (RMDs) in adults and children in 
language that can be used in conversations with the lay public, media, healthcare providers 
and other stakeholders. Based on the literature review, several elements were deemed 
important for inclusion in the description of RMDs. First, RMDs encompass many different 
diseases that can affect individuals at any age, including children. Second, there are various 
pathophysiological pathways underlying different RMDs. Third, the impact of RMDs on 
individuals and society should be emphasized. The working group agreed that the language 
should be comprehensible to the lay public. Thus, the following description of RMDs has 
been developed: “Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of 
diseases that commonly affect the joints, but can affect any organ of the body. There are 
more than 200 different RMDs, affecting both children and adults. They are usually caused by 
problems of the immune system, inflammation, infections or gradual deterioration of joints, 
muscles and bones. Many of these diseases are long term and worsen over time. They are 
typically painful and Iimit function. In severe cases, RMDs can result in significant disability, 
having a major impact on both quality of life and life expectancy.” This description can be 
used by rheumatology groups, researchers and those who work in advocacy and education 
related to RMDs. 
  
The field of rheumatology encompasses a wide range of medical conditions that affect many 
organ systems. These conditions reflect diverse pathogenic mechanisms and result in 
functional limitations, diminished quality of life and increased patient mortality. In addition, 
although rheumatic conditions in total are among the most common of all medical 
problems, many of the individual diseases are uncommon or even rare. This situation results 
in an ever-present dilemma for the field. Most of the public and policy makers around the 
world do not know about many of the rheumatic and musculoskeletal diseases (RMDs) and 
even if they have heard of them, there is broad lack of awareness about the complexity and 
enormous importance of this area of medicine.  
To further public awareness and support policies directed toward lessening the impact of 
these diseases on patients and society, a working group from the European League Against 
Rheumatism (EULAR) and the American College of Rheumatology (ACR), consisting of 
practicing and academic rheumatologists, a patient representative and a rheumatology 
health professional, have developed a formal description of these conditions. The goal of 
this effort was to create a succinct general statement describing RMDs in adults and children 
in language that can be used in conversations with the general population with and without 
RMDs; media; healthcare providers; policy makers at local, national and international level; 
health insurance companies; charities; employers and other stakeholders. 
Several elements were deemed important for inclusion in the description of RMDs by the 
group. First, it should be emphasised that RMDs encompass many different diseases that can 
affect persons at any age, including children. Second, it should be clear that there are 
various pathophysiological causes of RMDs. Third, the impact of RMDs on individuals and 
society should be emphasized. Finally, the language should be easily understood by the lay 
public. 
Here we will discuss various aspects that provide relevant background information, which 
can be used during the discussion about the importance of RMDs with the relevant 
stakeholders. 
 
 
 
 
 
Methodology 
 
The participants of the working group were selected based on their position in the 
respective organisations. For EULAR this was the president, the chair of the EULAR standing 
committee of clinical affairs, the EULAR liaison to the ACR, and a patient representative. For 
the ACR, the president and president-elect of the ACR, the president of the ARHP, and the 
president of the Rheumatology Research Foundation were included. The group met once in 
person, had one TC and all other exchanges were conducted by email. There was a scoping 
review of the literature with emphasis on grey literature such as reports from the European 
Union. 
 
RMDs encompass many different diseases that can affect persons at any age, including 
children 
 
Data suggest that there are over 200 RMDs; some conditions are very common, while others 
are rare. Lists of RMDs have been compiled in a number of publications and survey results. 
For example, the ACR website features a detailed list as does the EULAR website. [1,2] The 
latter is considered the official list as applied by the European Union (EU) of Medical 
Specialists (EUMS). [see appendix] In addition, the Arthritis Foundation, a patient 
organization in the USA as well as the ACR maintain patient-oriented lists of RMDs. [3,4]  
Well-known and prevalent examples of RMDs are rheumatoid arthritis, osteoarthritis and 
gout. According to a conservative estimate of the United Nations, symptomatic 
osteoarthritis, or degenerative joint disease, affects 15% of people worldwide, and it is 
estimated that by 2050, over 130 million people will suffer from osteoarthritis worldwide 
and 40 million will be severely disabled. [5]  
Rheumatoid arthritis is the most common autoimmune inflammatory form of arthritis and 
affects approximately 1 in 100 persons worldwide, with women affected twice as commonly 
as men. [6] Gout is the most common cause of inflammatory arthritis in men and has a 
prevalence in the US and Europe of about 4%. [7,8] 
Many other RMDs are less common, but cause significant morbidity and mortality. For 
example, systemic lupus erythematosus (SLE), which affects women approximately 9 times 
more frequently than men, is a systemic autoimmune disease that frequently causes 
arthritis and dysfunction of connective tissues among many other systemic manifestations. 
[9,10] The overall life-time risk for developing an inflammatory RMD including rheumatoid 
arthritis, gout, lupus and others for an adult in the US has been calculated as 1 in 12 for 
females, and 1 in 20 for males. [11] Many RMDs are uncommon or rare, which contributes to 
the lack of familiarity and/or experience with many RMDs on the part of general 
practitioners. RMDs frequently affect joints resulting in arthritis, but also frequently involve 
other internal organs and the skin. Although arthritis is commonly considered as a disease of 
aging, many RMDs – including many that cause disabling arthritis – occur in children. Lack of 
awareness of these conditions in both children and adults can lead to excessive and 
unnecessary damage and disability. [12-15] 
 
 
There are various pathophysiological pathways of RMDs.  
 
Review of these many diseases and conditions indicate that they develop through a diverse 
range of pathogenic pathways, most of which are not completely understood. Many result 
from dysregulation and activation of immune mechanisms that lead to inflammation and 
tissue damage. Some of these are classified as autoimmune diseases. Other RMDs result 
from acute or chronic damage to musculoskeletal structures including bone, cartilage, 
muscle, tendon, ligament and blood vessels. Other primary metabolic, endocrine, neurologic 
and infectious diseases can lead to secondary dysfunction and damage of musculoskeletal 
tissue. For example, prolonged hyperglycaemia in diabetes can result in changes in the 
structure of tendons and other soft tissues resulting in impaired mobility and joint function.  
The metabolic changes of the iron-storage disease hemochromatosis can result in 
degenerative arthritis in the hands. In addition, an increasing number of genetic variations 
and mutations are associated with the development of RMDs.  
 
 
RMDs result in a major burden for both the individual and society.  
 
Many of the diseases are chronic and as they can start as early as during childhood (e.g. 
juvenile idiopathic arthritis) or young adulthood (e.g. spondyloarthritis), patients suffer with 
their disease for decades. Moreover, most RMDs worsen over time with increasing impact 
on both the physical and psychological condition of the patient. Some patients die 
prematurely as a result of the condition or co-morbidities, although if appropriately treated, 
mortality is relatively low in most of these conditions.  
Large population studies emphasize that RMDs are highly prevalent worldwide. The 
eumusc.net project is a collaboration of 22 organizations in 17 member states of the EU 
investigating musculoskeletal health in Europe. [16] Their report summarizes the 
epidemiology of major RMDs, impact on the individual and society, and management and 
health services utilization. They concluded that musculoskeletal problems are the most 
common cause of severe long-term pain and disability in the EU and lead to significant 
healthcare and social support costs. Moreover, RMDs are a major cause of loss of work 
productivity resulting in significant economic costs and may have serious impact on quality 
of life, affecting those with the conditions and their relatives.  
Musculoskeletal pain is prevalent in the EU with just over one-fifth (22%) of the population 
reporting current or long-term muscle, bone and joint problems in a survey performed by 
the European Union in 2007. [17] Exactly a quarter of all EU respondents say that at some 
point in their life they have experienced chronic (lasting for at least 3 months) restrictive 
pain affecting muscles, joints, neck or back which affected their ability to carry out activities 
of daily living. Such pain is reported more by women than by men (28% vs. 22%). 
Musculoskeletal pain is the second most common complaint underlying long-term treatment 
attributing to major health care costs. [17]. Twenty four percent of the respondents to the 
survey received long-term treatment for RMDs (second after hypertension with 36% of 
respondents). It is likely that the overall burden of arthritis is underestimated in virtually 
every population. A recent study from the US. using national data from a health interview 
survey and doctor-diagnosed arthritis and symptoms revealed that arthritis affected 91.2 
million (36.8%) of the adult population, including about 29% of men and 55% of women 
between the ages of 18 and 65. [18]  
RMDs are the most frequent reason among non-infectious diseases to consult the primary 
care physician in the UK in 2003, and this is increasing with age and higher in female patients 
in all age categories. [16] In Germany 11.2% of the total cost of illness in 2008 were spent on 
musculoskeletal and connective tissue diseases. [16]. These numbers appear to be rapidly 
increasing. For example, a recent report provides data on doctor-diagnosed osteoarthritis in 
the US between 2013 and 2015. [19] A total of 54.4 million Americans (22.7%) had doctor-
diagnosed osteoarthritis and this percentage was even higher among adults with heart 
disease (49.3%), diabetes (47.1%) and obesity (30.6%). In 2012, 54% of people in the U.S 
over age 18 reported suffering a musculoskeletal problem and the prevalence approached 
75% for those aged 65 and older (BMUSUS)[20].  Several factors have an impact on the 
prevalence of RMDs, including gender, age, BMI and physical activity. As the population is 
aging this has a major impact on the prevalence of RMDs. For example, the EU will have 58 
million more people aged 65 and over in 2050 in comparison to 2004. [16]. Similarly, obesity 
is increasing, which again will lead to a higher prevalence of RMDs. [16]  
RMDs have led to significant reduction in function and quality of life as well as increased 
disability. Among those with osteoarthritis, 43.5% of the adults experienced limitations in 
activity attributable to osteoarthritis, and there was a significant increase of 20% in the 
proportion of adults reporting these limitations since 2002. The Disability Adjusted Life Year 
(DALY) is a measure to compare impact of various diseases on disability and can be 
interpreted as the loss of 1 year of healthy life. The World Health Organization (WHO listed 
osteoarthritis as the 8th leading cause of impact measured by DALYs in their report on global 
burden of disease. [21] Another way of assessing the impact on disability is the Years Lived 
with Disability (YLD). The WHO listed Musculoskeletal diseases as the third cause for 
disability among non-communicable diseases assessed by YLDs. And among musculoskeletal 
diseases, osteoarthritis was the most common disease followed by RA, ‘other 
musculoskeletal diseases’ and gout. [22]. As common and impactful as musculoskeletal 
diseases are, such surveys do not always include the entire range of RMDs. This further 
underscores the high prevalence and cost of these conditions and emphasizes the need for a 
unifying definition of RMD. An example of defining the global burden of ‘other 
musculoskeletal disorders’ was presented in a large study in 2010. [23,24] 
The International Quality of Life Assessment project examined the effect of multiple chronic 
conditions on populations in Denmark, France, Germany, Italy, Japan, the Netherlands, 
Norway and the US using the SF-36. This showed that arthritis, chronic lung disease and 
congestive heart failure were the conditions with the highest impact on SF-36 physical 
summary score. RA had a significant negative effect on the SF36 mental summary score. 
Arthritis had the highest impact on health-related quality of life in the general population 
[25]. A large survey study in the Netherlands which compared health related quality of life 
(using SF-36 or SF-24) across a wide range of long term conditions found that people with 
musculoskeletal conditions (included are back impairments, RA, osteoarthritis/other joint 
complaints) reported the lowest levels of physical functioning, role functioning and pain. 
[26] 
A Spanish study found that rheumatic diseases are among the diseases that produce the 
largest impairment in Health-Related Quality of Life (HRQoL) and daily functioning. [27] 
When the definition of the burden of disease includes a measure of function and of HRQoL 
that is weighted by the prevalence of disease, RMDs, as a group, may be considered on a par 
with other major diseases such as neurological, cardiac, or pulmonary diseases. [16] 
For many of the RMDs, it is important to recognize the disease early to have the best option 
to start treatment early and prevent or limit long-term consequences. To achieve this, 
EULAR has started the awareness campaign ‘Don’t delay, connect today’. The best example 
is rheumatoid arthritis. Early diagnosis, improved treatment options and applying treat to 
target principles has not only improved the percentage of patients in (sustained) remission, 
but also improved quality of life and work productivity. [28,29] Even overall excess mortality 
in patients with rheumatoid arthritis in comparison to the general population, which was 
apparent in previous decades, is lower and even no longer present when diagnosed and 
treated early and intensively. [30,31] 
Cause specific morbidities, such as cardiovascular disease, are greater in many of the RMDs, 
and may also be declining with improved disease management. [32] 
 
Workforce taking care of patients with RMDs  
 
A range of practitioners manage musculoskeletal problems. These include medical 
specialists, general practitioners, community pharmacists, physical therapists 
(physiotherapists, chiropractors), occupational therapists, and behavioural therapists 
(counsellors, psychologists and social workers). Rheumatologists, including pediatric 
rheumatologists, are the specialists with the most broad and specific training for diagnosing 
and treating RMDs.  Rheumatology specialty training standardized by EUMS across the EU 
and the Accreditation Council for Graduate Medical Education (ACGME) in the U.S. requires 
proficiency in general internal medicine followed by detailed training in the pathogenesis, 
diagnosis and management of the entire range of RMDs. [1,2] 
The number of practicing rheumatologists varies widely. The average number of 
rheumatologists in EU is 1.7 per 100.000 inhabitants, ranging from 0.5 in Ireland to 4.2 in 
France. [16].  Similarly, in the U.S. the number of rheumatologists ranges from greater than 2 
per 100,000 in heavily populated regions to less than 1.5 per 1000,000 in more rural regions. 
[30] However, due to a variety of factors affecting physician workforce, including the 
increasing prevalence of RMDs, these numbers are changing rapidly. For example, recent 
workforce projections in the U.S. estimate that by 2025 the average number of 
rheumatologists in the large majority of the country will be 0.5 - 1.0 per 100, 000 
inhabitants. [33] There is also a severe shortage of pediatric rheumatologists as 
substantiated by a survey in the US. [34] Other specialists caring for patients with RMDs are 
orthopedic surgeons, internists and rehabilitation specialists. There is also a wide variation in 
the workforce of allied health professionals. The number of physiotherapists varies 
enormously across EU countries from 34 in Ireland to 234 per 100.000 inhabitants in Finland. 
[16] Similarly, the variation in occupational therapists ranges from 2 in Italy to 100 per 
100.000 inhabitants in Sweden and Denmark. [16] In contrast, in the US there were about 
114,600 occupational therapy jobs listed in 2014 for a population of close to 318,500,000 
(360 per 100.000). [35] 
 
Based on the above data and considerations, the following common language description of 
RMDs was endorsed by both EULAR and ACR. 
 
Rheumatic and musculoskeletal diseases (RMDs) are a diverse group of diseases that 
commonly affect the joints, but can affect any organ of the body. There are more than 200 
different RMDs, affecting both children and adults. They are usually caused by problems of 
the immune system, inflammation, infections or gradual deterioration of joints, muscles and 
bones. Many of these diseases are long term and worsen over time. They are typically painful 
and Iimit function. In severe cases, RMDs can result in significant disability, having a major 
impact on both quality of life and life expectancy. 
 
 
 
 
Summary 
 
The description of RMDs is a succinct statement in common language detailing many of the 
important aspects of these conditions.  Given the prevalence and impact of RMDs as well as 
the availability of effective management options, it is important to be able to communicate 
clearly what RMDs are with the public and stakeholders. It is especially imperative to 
communicate the impact and importance of RMDs to healthcare policy makers.  
The many unanswered questions about the causes of RMDs, the importance of improved 
diagnosis for RMDs and clear need for effective and safe treatments that are unavailable for 
many of these diseases emphasize the importance of increased research on RMDs. At the 
same time, the fact that many recent advances have been made in developing new therapies 
for RMDs so that many people are now treated very effectively – with prevention of 
disability and comorbidity – emphasizes how critical it is that patients have ready access to 
diagnosis and care for these conditions. We hope that the description of RMDs provided in 
this manuscript will enable improved communication about and advocacy for these 
conditions and the patients who suffer from them.  
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